- Optimi Health has priced its underwritten public offering at US$6.25 per common share, raising approximately US$15M ahead of its Nasdaq Capital Market debut under the ticker “OPTH” on May 20, 2026. The offering includes 2.4M common shares, with the underwriter holding an option to purchase an additional 360K shares.
- The Canadian psychedelic pharmaceutical company said the proceeds will support production scale-up, distribution expansion, entry into new markets including the US, and broader commercial growth initiatives.
- The offering follows Optimi’s uplisting to Nasdaq and comes alongside a 1-for-30 share consolidation that became effective on May 19, 2026. Following the consolidation, the company expects to have ~3.2M common shares outstanding before giving effect to the offering.
- Optimi, which focuses on manufacturing and distributing finished psychedelic drug products, continues to position itself for broader global expansion as interest in psychedelic-based therapeutics and mental health treatments grows.
Takeaways
Optimi is using its Nasdaq uplist and 1‑for‑30 share consolidation to raise roughly 15 million US dollars at scale, then plow the cash into making and selling more MDMA and psilocybin products, including in new markets like the US.
For the psychedelic drugs space, this move shows that at least some Canadian manufacturers are reaching the point where they can list on major US exchanges, supply GMP‑grade products to programs in places like Australia and Canada’s Special Access Program, and start competing for a slice of a psychedelic therapies market that analysts expect to grow strongly over the next decade.
Source: PRnewswire
